| Literature DB >> 22958270 |
Halime Sc Büker1, Esen Demir, Zeki Yüncü, Figen Gülen, Levent Midyat, Remziye Tanaç.
Abstract
AIM: Inhalant abuse is a prevalent and often overlooked form of substance abuse in adolescents. Chronic inhalant abuse can damage respiratory, cardiac, renal, hepatic, and neurologic systems. This study aims to determine the physiologic effects of inhaling solvents on the respiratory functions.Entities:
Year: 2011 PMID: 22958270 PMCID: PMC3463073 DOI: 10.1186/2049-6958-6-3-161
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
The Distribution of Inhalants Being Abused Among the Study Subjects
| Volatile Substance Abuse | n (%) |
|---|---|
| Paınt thinner | 2 (6.5%) |
| Glue (trademark, Bally) | 25 (80.6%) |
| Thinner + Bally | 4 (12.9%) |
The Age of Onset, and The Rates of Abuse and Addiction, for each Substance
| Substance name | Age of onset (years) Mean ± SD | Abuse n (%) | Addiction n (%) |
|---|---|---|---|
| Cigarette smoke | 11.85 ± 2.69 | 1 (3.2%) | 27 (87.1%) |
| Inhalant | 14.16 ± 2.16 | 0 | 31 (100%) |
| Alcohol | 14.23 ± 1.97 | 16 (51.6%) | 5 (16.1%) |
| Hashish | 14.46 ± 2.06 | 9 (29.0%) | 17 (54.8%) |
| Benzodiazepine | 14.75 ± 1.65 | 6 (19.4%) | 6 (19.4%) |
| Cocaine | 15.0 ± 2.58 | 3 (9.7%) | 1 (3.2%) |
| Ecstasy | 15.17 ± 1.42 | 8 (25.8%) | 9 (29.0%) |
Distribution of Respiratory-Related Complaints Amongst Group (N = 31) of Volatile Substance Abusers
| N | % | |
|---|---|---|
| Nasal congestion | 14 | 45.16 |
| Sputum | 12 | 38.71 |
| Exercise intolerance | 10 | 32.26 |
| Coughing | 7 | 22.58 |
| Chest pain | 5 | 16.13 |
| Shortness of breath | 3 | 9.68 |
| Tachypnea | 3 | 9.68 |
| Wheezing | 2 | 6.45 |
| Sneezing | 2 | 6.45 |
| Runny nose | 2 | 6.45 |
Demographic Characteristics of the Groups
| Study group (n = 31) Mean ± SD | Control group (n = 13) Mean ± SD | p• | |
|---|---|---|---|
| Age (years) | 17.94 ± 1.52 | 18.78 ± 0.64 | 0.066 |
| Weight (kg) | 67.88 ± 14.16 | 64.61 ± 8.54 | 0.455 |
| Height (cm) | 173.61 ± 8.92 | 176.30 ± 4.95 | 0.315 |
•: Student's t-test.
Evaluating the pulmonary function tests for the study and control groups
| Study group (n = 29) Mean ± SD | Control group (n = 13) Mean ± SD | P• | |
|---|---|---|---|
| FEV1 (L) | 3.78 ± 0.59 | 4.23 ± 0.59 | 0.029* |
| FEV1 (%) | 97.75 ± 13.85 | 103.38 ± 10.75 | 0.202 |
| FVC (L) | 3.90 ± 0.62 | 4.35 ± 0.71 | 0.046* |
| FVC (%) | 84.03 ± 11.66 | 88.69 ± 10.88 | 0.229 |
| PEF (L/secec) | 6.85 ± 1.08 | 9.54 ± 0.85 | 0.001** |
| PEF (%) | 80.44 ± 16.97 | 110.23 ± 17.88 | 0.001** |
| FEV1/FVC | 97.10 ± 4.75 | 97.61 ± 3.30 | 0.727 |
| FEV1/FVC (%) | 117.00 ± 5.55 | 117.37 ± 4.53 | 0.866 |
| MEF25-75 (L/sec) | 4.94 ± 1.22 | 6.35 ± 1.21 | 0.001** |
| MEF25-75 (%) | 114.65 ± 22.95 | 138.92 ± 32.15 | 0.008** |
•: Student's t-test.
*p < 0.05.
**p < 0.01.
Comparing the reduction in FVC with the pulmonary system complaints in the study group
| FVC > 80% (n = 17) | p• | ||||
|---|---|---|---|---|---|
| n | % | n | % | ||
| 2 | 16.7 | 4 | 23.5 | 1.000 | |
| 3 | 25.0 | 0 | 0 | 0.060 | |
| 0 | 0 | 2 | 11.8 | 0.498 | |
| 0 | 0 | 1 | 5.9 | 1.000 | |
| 2 | 16.7 | 2 | 11.8 | 0.706 | |
| 4 | 33.3 | 6 | 35.3 | 0.913 | |
| 5 | 41.7 | 4 | 23.5 | 0.298 | |
| 0 | 0 | 2 | 11.8 | 0.498 | |
| 0 | 0 | 2 | 11.8 | 0.498 | |
| 5 | 41.7 | 8 | 47.1 | 0.774 | |
•: Fisher's Exact test, where Chi-Square test would be necessary.
Comparing the reduction in FVC, with HRCT and Scintigraphy Findings
| FCV | |||
|---|---|---|---|
| ≤ | > 80% (n = 15) | ||
| Small airways disease | 0 | 2 (13.3%) | 0.280 |
| Subpleural nodule | 4 (50.0%) | 2 (20.0%) | 0.136 |
| Centrilobular nodule | 2(25.0%) | 0 | 0.043* |
| Atelectasis | 2 (25.0%) | 0 | 0.043* |
| Normal | 1 (12.5%) | 11 (73.3%) | 0.009** |
| Perfusion disorder | 3 (33.3%) | 4 (28.6%) | 1.000 |
| Ventilation disorder | 1 (11.1%) | 3 (25.0%) | 0.603 |
Definition of abbreviations: FVC, forced vital capacity; HRCT, high resolution computerized tomography.
•: Chi-square test.
*p < 0.05.
**p < 0.01.